Supply Chain Intelligence

Plus Therapeutics, Inc. Supply Chain

PSTV supply chain intelligence for Plus Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

PSTV ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
2Customers
3Debt Items
20Related Chains

Plus Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
LAKE-STREET-CAPITAL-MARKETS-LLC LAKE-STREET-CAPITAL-MARKETS-LLC 92% On January 13, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as the underwriter (the “Unde…
CANACCORD-GENUITY-LLC CANACCORD-GENUITY-LLC 90% The Company will pay the Agent a commission of 3.0% of the gross proceeds from the sale of Shares by the Agent under the Distribution Agreement.
NKTR Nektar Therapeutics 72% iolabeled nanoliposome platform was developed by a multi-institutional consortium based in Texas at the Mays Cancer Center / UTHSCSA MD Anderson Cancer Center led by Dr. Andrew Brenner, MD, PhD, who …
NKTR Nektar Therapeutics 72% Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV graph: iolabeled nanoliposome platform was…

Plus Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
LINCOLN-PARK-CAPITAL-FUND LINCOLN-PARK-CAPITAL-FUND 90% Under the terms and subject to the conditions of the Lincoln Park Purchase Agreement, we have the right, but not the obligation, to issue shares of our common stock to Lincoln Park.
BDRX Biodexa Pharmaceuticals Plc 72% Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund ha…

Plus Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PSTV-DEBT-11931 Xbrl Convertible 90% xbrl convertible detail from xbrl 2015-12-31.
PSTV-DEBT-11930 Warrants outstanding: 50 90% xbrl warrant detail from xbrl 2025-12-31.
PSTV-DEBT Debt stack $725,000 90% Market cache reports total debt of $725,000.

Plus Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Plus Therapeutics, Inc..

Plus Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
PSTV-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 24 tracked holders.

Plus Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
NKTR Nektar Therapeutics 100.00 1 ['supplier']
BDRX Biodexa Pharmaceuticals Plc 100.00 1 ['customer']
TARA Protara Therapeutics, Inc. 50.00 2
BHC Bausch Health Companies Inc. 50.00 2
CNSP CNS Pharmaceuticals, Inc. 50.00 2
CGON CG Oncology, Inc. 50.00 2
SABSW SAB Biotherapeutics, Inc. 50.00 2
CRSP CRISPR Therapeutics AG 50.00 2
HCWB HCW Biologics Inc. 50.00 2
COGT Cogent Biosciences, Inc. 50.00 2
GSK GSK plc 50.00 2
TPST Tempest Therapeutics, Inc. 50.00 2
FLG Flagstar Bank, National Association 50.00 2
IOBTQ IO Biotech, Inc. 50.00 2
IMA ImageneBio, Inc. 50.00 2
TKPHF Takeda Pharmaceutical Company Limited 50.00 2
SGMO Sangamo Therapeutics, Inc. 50.00 2
ASND Ascendis Pharma A/S 50.00 2
SNYNF Sanofi 50.00 2
TAK Takeda Pharmaceutical Company Limited 50.00 2
View PSTV supply chain intel →

Explore the full interactive supply chain map for Plus Therapeutics, Inc..

Open PSTV supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map